Expression, purification and crystallization of CTB-MPR, a candidate mucosal vaccine component against HIV-1

Lee, H.-H.; Cherni, I.; Yu, H.; Fromme, R.; Doran, J.D.; Grotjohann, I.; Mittman, M.; Basu, S.; Deb, A.; Dörner, K.; Aquila, A.; Barty, A.; Boutet, S.; Chapman, H.N.; Doak, R.B.; Hunter, M.S.; James, D.; Kirian, R.A.; Kupitz, C.; Lawrence, R.M.; Liu, H.; Nass, K.; Schlichting, I.; Schmidt, K.E.; Seibert, M.M.; Shoeman, R.L.; Spence, J.C.H.; Stellato, F.; Weierstall, U.; Williams, G.J.; Yoon, C.; Wang, D.; Zatsepin, N.A.; Hogue, B.G.; Matoba, N.; Fromme, P.; Mor, T.S.

doi:10.1107/S2052252514014900

Figure 6
The CTBMPR oligomeric state is affected by the concentration of the protein. SEC–HPLC fractions corresponding to the pentamer (a) and monomer (b) peaks (Fig. 5

) were subjected separately to a second SEC–HPLC purification. Absorbance is normalized to the highest peak.

IUCrJ

Volume 1| Part 5| August 2014| Pages 305-317

ISSN: 2052-2525

doi:10.1107/S2052252514014900

Open

access

Follow IUCrJ

Search IUCr Journals		doi		Advanced search
Author		volume	page